One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Zoetis  logo
Zoetis ZTS
$ 82.45 0.34%
report update icon

Quarterly report 2026-Q3
added 11-05-2026

Zoetis Balance Sheet 2025-2010 | ZTS

Brief balance sheet overview of Zoetis

Balance sheet changes are traced across five available annual reports between 2021 and 2025.

Assets moved from $13.9 billion to $15.5 billion, a rise of +11.3%. CAGR near 2.7% indicates restrained expansion.

Funding shifted toward liabilities: they gained +29.7%, compared with +11.3% for assets.

Equity funds just 21.5% of assets versus 32.7% previously. The balance sheet is sensitive to weaker results.

Each unit of equity supports 2.04x of net debt. This elevated load requires dependable cash generation.

Cash represents 14.9% of assets versus 25.1% initially, showing how the immediate liquidity reserve changed.

Retained earnings stand at $13.7 billion; the five-period change was +91.3%. This reflects accumulated business performance.

Conclusion

Zoetis 's balance sheet profile remains vulnerable. Lower liabilities and capital accumulation are the main routes to improvement.

Annual Balance Sheet Zoetis

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

Net Debt

6.78 B 3.28 B 4.57 B 3.01 B 3.15 B 3.03 B 4.52 B 4.85 B 3.39 B 3.74 B 3.71 B 2.77 B 3.05 B 265 M 496 M -

Long Term Debt

9.04 B 5.22 B 6.56 B 6.55 B 6.59 B 6.6 B 5.95 B 6.44 B 4.95 B 4.47 B 4.46 B 3.64 B 3.64 B 509 M 575 M -

Long Term Debt Current

52 M 51 M 48 M 43 M 41 M 40 M 35 M - - - 400 M - - - - -

Total Non Current Liabilities

9.9 B 6.06 B 7.41 B 7.36 B 7.56 B 7.67 B 7.03 B 7.37 B 5.71 B 5.03 B 5.04 B 4.18 B 4.18 B 1.1 B 1.13 B -

Total Current Liabilities

2.24 B 3.41 B 1.89 B 3.17 B 1.8 B 2.17 B 1.81 B 1.22 B 1.09 B 1.12 B 1.78 B 1.09 B 1.42 B - - -

Total Liabilities

12.1 B 9.47 B 9.3 B 10.5 B 9.36 B 9.84 B 8.84 B 8.59 B 6.8 B 6.15 B 6.82 B 5.27 B 5.6 B 2.22 B 1.98 B -

Deferred Revenue

- - - - - 8 M - - - - - - - - - -

Retained Earnings

13.7 B 12 B 10.3 B 8.67 B 7.19 B 5.66 B 4.43 B 3.27 B 2.11 B 1.48 B 876 M 709 M 276 M - - -

Total Assets

15.5 B 14.2 B 14.3 B 14.9 B 13.9 B 13.6 B 11.5 B 10.8 B 8.59 B 7.65 B 7.91 B 6.61 B 6.56 B 6.26 B 5.71 B -

Cash and Cash Equivalents

2.31 B 1.99 B 2.04 B 3.58 B 3.48 B 3.6 B 1.93 B 1.6 B 1.56 B 727 M 1.15 B 882 M 610 M 317 M 79 M 63 M

Book Value

3.33 B 4.77 B 4.99 B 4.4 B 4.54 B 3.77 B 2.71 B 2.18 B 1.79 B 1.5 B 1.09 B 1.34 B 962 M 4.04 B 3.74 B -

Total Shareholders Equity

3.33 B 4.77 B 5 B 4.4 B 4.54 B 3.77 B 2.71 B 2.18 B 1.77 B 1.49 B 1.07 B 1.31 B 940 M 4.04 B 3.74 B 3.34 B

All numbers in USD currency

Quarterly Balance Sheet Zoetis

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

188 M 190 M 193 M 197 M 204 M 210 M 173 M 174 M 181 M 181 M 184 M 188 M 191 M 188 M 180 M 186 M 186 M 161 M 158 M 151 M 160 M 147 M 159 M 163 M 167 M 155 M 159 M 164 M 169 M 169 M 134 M 6.44 B 6.44 B 6.44 B 4.95 B 4.95 B 4.95 B 3.72 B 3.72 B 4.47 B 4.47 B 4.46 B 4.46 B 4.46 B 3.23 B 3.24 B 3.24 B 3.62 B 3.64 B 3.64 B 3.64 B 3.64 B 3.64 B 3.64 B 3.64 B - - - - - - - -

Total Non Current Liabilities

9.1 B 9.87 B 9.87 B 9.9 B 7.95 B 6.14 B 6.06 B 6.06 B 7.42 B 7.41 B 7.39 B 7.41 B 7.42 B 7.36 B 7.35 B 7.36 B 6.13 B 6.14 B 6.17 B 7.56 B 7.55 B 7.63 B 7.64 B 7.67 B 7.72 B 8.27 B 7.05 B 7.03 B 7.54 B 7.5 B 7.48 B 7.37 B 7.34 B 5.65 B 5.72 B 5.71 B 5.52 B 4.27 B 4.28 B 5.03 B 5.08 B 5.11 B 5.1 B 5.04 B 3.77 B 3.82 B 3.76 B 4.16 B 4.14 B 4.18 B 4.18 B 4.18 B 4.08 B 4.12 B 4.13 B - - - - - - - -

Total Liabilities

11.8 B 11.9 B 11.9 B 12.1 B 9.76 B 9.5 B 9.44 B 9.47 B 9.12 B 9.2 B 9.3 B 9.3 B 9.03 B 9.13 B 9.26 B 10.5 B 9.01 B 9.19 B 9.2 B 9.36 B 9.02 B 9.72 B 9.7 B 9.84 B 10.1 B 10.1 B 8.78 B 8.84 B 8.59 B 8.58 B 8.57 B 8.59 B 8.34 B 6.62 B 6.72 B 6.8 B 7.27 B 6.06 B 6.01 B 6.15 B 6.12 B 6.15 B 6.27 B 6.82 B 5.43 B 5.4 B 5.12 B 5.25 B 5.14 B 5.24 B 5.3 B 5.6 B 5.39 B 5.44 B 5.42 B 2.22 B 2.22 B 2.22 B 2.22 B - - - -

Deferred Revenue

- - - - - - - - - - - - - - - - - - - - - 8 M 3 M 4 M 6 M 5 M 3 M 11 M 8 M 4 M 1 M 2 M 2 M 2 M 2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

15.2 B 14.7 B 14.2 B 13.8 B 13.6 B 12.9 B 12.4 B 12 B 11.8 B 11.1 B 10.7 B 10.3 B 10.1 B 9.54 B 9.04 B 8.67 B 8.53 B 8 B 7.63 B 7.19 B 7.04 B 6.49 B 6.1 B 5.66 B 5.53 B 5.05 B 4.76 B 4.43 B 4.22 B 3.79 B 3.5 B 3.27 B 3.07 B 2.72 B 2.4 B 2.11 B 2.14 B 1.84 B 1.65 B 1.48 B 1.42 B 1.19 B 1.02 B 876 M 943 M 795 M 832 M 709 M 661 M 531 M 395 M 276 M 207 M 109 M 13 M - - - - - - - -

Total Assets

15.1 B 15.1 B 15.2 B 15.5 B 15.2 B 14.5 B 14.1 B 14.2 B 14.4 B 14.2 B 14.3 B 14.3 B 14.1 B 13.7 B 13.8 B 14.9 B 13.7 B 13.8 B 13.9 B 13.9 B 13.7 B 14.1 B 13.8 B 13.6 B 13.7 B 13.1 B 11.5 B 11.5 B 11.3 B 11 B 10.9 B 10.8 B 10.5 B 8.6 B 8.69 B 8.59 B 9.29 B 7.8 B 7.65 B 7.65 B 7.72 B 7.52 B 7.45 B 7.91 B 6.69 B 6.6 B 6.43 B 6.59 B 6.53 B 6.52 B 6.4 B 6.56 B 6.26 B 6.26 B 6.14 B 6.26 B 6.26 B 6.26 B 6.26 B - - - -

Cash and Cash Equivalents

1.33 B 1.48 B 1.94 B 2.45 B 2.27 B 1.63 B 1.78 B 2.11 B 1.71 B 1.57 B 1.98 B 2.04 B 1.75 B 1.72 B 2.11 B 3.58 B 2.51 B 2.65 B 3.14 B 3.48 B 3.27 B 3.66 B 3.6 B 3.6 B 3.65 B 3.35 B 1.95 B 1.93 B 1.82 B 1.76 B 1.73 B 1.6 B 1.29 B 1.56 B 1.65 B 1.56 B 1.98 B 705 M 629 M 727 M 651 M 658 M 675 M 1.15 B 592 M 544 M 559 M 882 M 598 M 578 M 506 M 610 M 389 M 369 M 468 M 317 M 317 M 317 M 317 M 79 M - - -

Book Value

3.3 B 3.15 B 3.23 B 3.42 B 5.4 B 4.98 B 4.66 B 4.77 B 5.23 B 4.96 B 5.05 B 4.99 B 5.07 B 4.62 B 4.49 B 4.4 B 4.66 B 4.58 B 4.66 B 4.54 B 4.68 B 4.35 B 4.09 B 3.77 B 3.61 B 2.99 B 2.75 B 2.71 B 2.68 B 2.41 B 2.32 B 2.18 B 2.12 B 1.98 B 1.98 B 1.79 B 2.02 B 1.75 B 1.64 B 1.5 B 1.6 B 1.37 B 1.19 B 1.09 B 1.25 B 1.2 B 1.3 B 1.34 B 1.39 B 1.28 B 1.1 B 962 M 866 M 823 M 724 M 4.04 B 4.04 B 4.04 B 4.04 B - - - -

Total Shareholders Equity

3.3 B 3.15 B 3.23 B 3.42 B 5.54 B 5.16 B 4.86 B 4.84 B 5.23 B 4.96 B 5.05 B 4.99 B 5.07 B 4.62 B 4.49 B 4.4 B 4.66 B 4.58 B 4.66 B 4.54 B 4.68 B 4.35 B 4.09 B 3.77 B 3.61 B 2.99 B 2.75 B 2.71 B 2.68 B 2.41 B 2.32 B 2.18 B 2.12 B 1.98 B 1.98 B 1.79 B 2.02 B 1.75 B 1.64 B 1.5 B 1.6 B 1.37 B 1.19 B 1.09 B 1.25 B 1.2 B 1.3 B 1.34 B 1.39 B 1.28 B 1.1 B 962 M 866 M 823 M 724 M 4.03 B 4.03 B 4.03 B 4.03 B 3.74 B - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Zoetis , providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Sigilon Therapeutics Sigilon Therapeutics
SGTX
- - $ 728 M usaUSA
Rubius Therapeutics Rubius Therapeutics
RUBY
- -33.55 % $ 7.81 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
TRACON Pharmaceuticals TRACON Pharmaceuticals
TCON
- -1.38 % $ 46.8 M usaUSA
Mirati Therapeutics Mirati Therapeutics
MRTX
- - $ 3.3 B usaUSA
Revance Therapeutics Revance Therapeutics
RVNC
- - $ 309 M usaUSA
Allogene Therapeutics Allogene Therapeutics
ALLO
$ 0.93 -11.99 % $ 205 M usaUSA
InVivo Therapeutics Holdings Corp. InVivo Therapeutics Holdings Corp.
NVIV
- -37.48 % $ 476 K usaUSA
Epizyme Epizyme
EPZM
- - $ 249 M usaUSA
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
ORIC Pharmaceuticals ORIC Pharmaceuticals
ORIC
$ 8.9 -3.63 % $ 781 M usaUSA
Forward Pharma A/S Forward Pharma A/S
FWP
- -0.75 % $ 18.7 M danmarkDanmark
Orchard Therapeutics plc Orchard Therapeutics plc
ORTX
- 1.02 % $ 90.8 M britainBritain
La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company
LJPC
- - $ 154 M usaUSA
Oyster Point Pharma Oyster Point Pharma
OYST
- - $ 300 M usaUSA
Nabriva Therapeutics plc Nabriva Therapeutics plc
NBRV
- - $ 4.55 M irlandaIrlanda
Intercept Pharmaceuticals Intercept Pharmaceuticals
ICPT
- - $ 643 M usaUSA
NGM Biopharmaceuticals NGM Biopharmaceuticals
NGM
- - $ 127 M usaUSA
Regulus Therapeutics Regulus Therapeutics
RGLS
- - $ 155 M usaUSA
9 Meters Biopharma 9 Meters Biopharma
NMTR
- -42.97 % $ 1.05 M usaUSA
Chinook Therapeutics Chinook Therapeutics
KDNY
- - $ 2.6 B usaUSA
Lumos Pharma Lumos Pharma
LUMO
- - $ 35.3 M usaUSA
Syros Pharmaceuticals Syros Pharmaceuticals
SYRS
- -8.44 % $ 3.4 M usaUSA
NanoViricides NanoViricides
NNVC
$ 1.44 8.27 % $ 29.1 M usaUSA
Gamida Cell Ltd. Gamida Cell Ltd.
GMDA
- -18.25 % $ 5.04 M israelIsrael
GT Biopharma GT Biopharma
GTBP
$ 3.99 -7.64 % $ 22 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 1.52 -3.8 % $ 3.75 B israelIsrael
VistaGen Therapeutics VistaGen Therapeutics
VTGN
$ 0.18 -0.46 % $ 6.85 M usaUSA
C4 Therapeutics C4 Therapeutics
CCCC
$ 3.0 -4.76 % $ 249 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 1.67 -0.6 % $ 2.75 M israelIsrael
Cytokinetics, Incorporated Cytokinetics, Incorporated
CYTK
$ 56.2 1.92 % $ 6.75 M usaUSA
Curis Curis
CRIS
$ 0.66 -5.68 % $ 8.69 M usaUSA
Exelixis Exelixis
EXEL
$ 71.0 -1.04 % $ 19.3 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Amgen Amgen
AMGN
$ 465.26 0.01 % $ 250 B usaUSA
Biogen Biogen
BIIB
$ 253.37 -0.59 % $ 37.1 B usaUSA
Edesa Biotech Edesa Biotech
EDSA
$ 2.01 -19.28 % $ 11.4 M usaUSA
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$ 15.12 -0.72 % $ 978 M usaUSA
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 6.78 0.89 % $ 296 M usaUSA
Fulcrum Therapeutics Fulcrum Therapeutics
FULC
$ 3.72 -0.13 % $ 236 M usaUSA
Immutep Limited Immutep Limited
IMMP
$ 3.53 -7.11 % $ 5.14 B australiaAustralia
Iovance Biotherapeutics Iovance Biotherapeutics
IOVA
$ 8.09 -1.04 % $ 2.89 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
$ 0.37 28.7 % $ 2.91 M israelIsrael
Armata Pharmaceuticals Armata Pharmaceuticals
ARMP
$ 3.71 -2.5 % $ 134 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 141.12 5.34 % $ 7.02 B usaUSA
Keros Therapeutics Keros Therapeutics
KROS
$ 9.32 1.64 % $ 347 M usaUSA
Champions Oncology Champions Oncology
CSBR
$ 4.85 0.21 % $ 67.1 M usaUSA
Fennec Pharmaceuticals Fennec Pharmaceuticals
FENC
$ 10.6 -2.12 % $ 303 M usaUSA